Enzon Pharmaceuticals Stock Forecast, Price & News

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

How has Enzon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ENZN stock has increased by 123.3% and is now trading at $0.3780.
View which stocks have been most impacted by COVID-19.

Are investors shorting Enzon Pharmaceuticals?

Enzon Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,700 shares, an increase of 818.8% from the October 31st total of 1,600 shares. Based on an average trading volume of 147,200 shares, the days-to-cover ratio is currently 0.1 days.
View Enzon Pharmaceuticals' Short Interest.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) released its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($0.01) earnings per share for the quarter. Enzon Pharmaceuticals had a negative trailing twelve-month return on equity of 10.09% and a negative net margin of 117.79%.
View Enzon Pharmaceuticals' earnings history.

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the following people:

• Richard L. Feinstein, Secretary, Chief Executive & Financial Officer

Who are some of Enzon Pharmaceuticals' key competitors?

Some companies that are related to Enzon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Incyte (INCY), Exact Sciences (EXAS), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of ENZN's competitors.

What other stocks do shareholders of Enzon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Golar LNG Partners (GMLP), Washington Prime Group (WPG), DHT (DHT), Hallador Energy (HNRG) and Medical Marijuana (MJNA).

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.38.

How much money does Enzon Pharmaceuticals make?

Enzon Pharmaceuticals has a market capitalization of $28.05 million and generates $50 thousand in revenue each year. The biotechnology company earns $-1.31 million in net income (profit) each year or ($0.04) on an earnings per share basis.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is www.enzon.com.

Where are Enzon Pharmaceuticals' headquarters?

Enzon Pharmaceuticals is headquartered at 20 Commerce Drive Suite 135, Cranford NJ, 07016.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at (732) 980-4500, via email at [email protected], or via fax at 732-980-4585.